Dr Markus Schade has worked for over 18 years in the pharmaceutical industry. He started his career as a co-founder of the biotech company Combinature Biopharm AG. Next Markus worked for the global Pharma-CRO Evotec AG before he joined the BigPharma companies Pfizer and thereafter AstraZeneca in the UK. Since 2012 Markus does pre-clinical drug discovery with the pain specialist Grunenthal GmbH in Germany. He has specialized in the field of Fragment-based Drug Discovery (FBDD), where he has successfully led many projects and published several peer-reviewed articles and patents.
Markus studied biochemistry at the University of Hannover, Germany, and the Massachusetts Institute of Technology, USA, and holds a Ph.D. in structural biology from the Free University Berlin, Germany. Presently he holds the position of a scientific director at Grunenthal.